• HIT-SIOP PNET 4 a prospective randomized controlled trial of hyperfractionated versus conventionally fractionated radiotherapy in standard risk medulloblastoma. (chiuso arruolamento ma ancora in uso in attesa nuovo protocollo)
  • Protocollo di diagnosi e cura del medulloblastoma metastatico e/o a istologia sfavorevole (HART)
  • 2° protocollo AIEOP di diagnosi e cura degli ependimomi dell'età pediatrica
  • SIOP-LGG 2004 cooperative multicenter study for children and adolescents with low grade glioma
  • Protocol CLDE225C2301 Novartis: A Phase III, multi-center, open-label, randomized,controlled study of the efficacy and safety of oral LDE225 versus temozolomide in patients with Hh-pathway activated relapsed medulloblastoma.
  • Protocol for treatment of CNS high risk malignant tumors in patients aged < 3 years
  • BO25041 / ITCC-019 / HGG-01: An open-label, randomized, multi-centre comparative study of bevacizumab-based therapy in paediatric patients with newly diagnosed supratentorial high-grade glioma.
  • Studio epidemiologico "MOBI-KIDS - Rischio di tumori cerebrali ed esposizione a campi elettromagnetici a radiofrequenza nei bambini e negli adolescenti: uno studio multicentrico internazionale.
  • European Rhabdoid Registry - EU-RHAB.
  • SIOP CNS GCT II: prospective trial for the diagnosis and treatment of children, adolescents and young adults with Intracranial Germ Cell Tumours.

  • NB-AR-01 primo studio cooperativo europeo per il neuroblastoma ad alto rischio (studio fase III)
  • European infant neuroblastoma study (chiuso arruolamento ma ancora in uso in attesa nuovo protocollo)
  • Prot. LINES - European Low and Intermediate Risk Neuroblastoma – a Siopen Study – EudraCT number: 2010-021396-81
  • Studio clinico di fase II con Topotecan in associazione a Vincristina-Adriamicina nel trattamento di pazienti in età pediatrica con neuroblastoma resistente o in recidiva (Fase II)

  • CA180-226 a phase II study of Dasatinib therapy in children and adolescent with newly diagnosed chronic phase chronic myelogenous or with Ph+ leukemias resistant or intolerant to Imatinib.(Studio di Fase II)
  • CAMN 107A2203